Leading breast cancer therapy, Herceptin keeps exclusivity by next year

In the domestic breast cancer treatment market, the Roche’s influence is expected to be kept, at least, by 2017.

This is because Celltrion which acquire approval of the Herceptin’s biosimilar, ‘Herzuma,’ has recently failed in the nullification trial of the Herceptin’s composition patent.

According to the industry on the 7^th, the Patent Court raised the Roche’s hand at the Herceptin patent su...